Indivior logo

INDV - Indivior News Story

155.3p 2.3  1.5%

Last Trade - 07/05/21

Market Cap £1.14bn
Enterprise Value £666.3m
Revenue £482.4m
Position in Universe 409th / 1821

Indivior PLC - Indivior to Participate in Upcoming Conferences

Tue 10th November, 2020 7:00am
RNS Number : 7452E
Indivior PLC
10 November 2020
 

 

Indivior Announces Participation in Upcoming Investor Conferences

Slough, United Kingdom and Richmond, Virginia - November 10, 2020 - Indivior PLC (LON: INDV) today announced its participation in the following upcoming investor conferences:

·    November 16th, 8:00 AM US Eastern Time (ET): Stifel Virtual Healthcare Conference (link).

·    November 17th, 12:00 PM US Eastern Time (ET): Jefferies Virtual Global Healthcare Conference (link).

About Indivior 

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of addiction. Indivior is dedicated to transforming addiction from a global human crisis to a recognized and treated chronic disease. 

Building on its global portfolio of opioid dependence treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Headquartered in the United States in Richmond, VA, Indivior employs more than 700 individuals globally and its portfolio of products is available in over 40 countries worldwide. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/indivior. 

For Further Information

Investor Enquiries

 

Jason Thompson

VP, Investor Relations Indivior PLC

+1 804 402 7123

jason.thompson@indivior.com

Media Enquiries

Jonathan Sibun
 

Tulchan Communications

US Media Inquiries

 

+44 207 353 4200
 

+1 804 594 0836

Indiviormediacontacts@indivior.com

 

 

-ends-

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAPFNEDLEFFA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.